Olimel N9E
Composition:
active substances: alanine; arginine; aspartic acid; glutamic acid; glycine; histidine; isoleucine; leucine; lysine acetate (equivalent to lysine); methionine; phenylalanine; proline; serine; threonine; tryptophan; tyrosine; valine; sodium acetate trihydrate; potassium chloride; magnesium chloride hexahydrate; sodium glycerophosphate, hydrated; glucose, monohydrate (equivalent to anhydrous glucose); calcium chloride, dihydrate; refined olive oil; refined soybean oil.
Emulsion for infusion.
glucose solution with calcium and amino acid solution with electrolytes: clear, colorless or slightly yellow, practically free from particles;
lipid emulsion: homogeneous milky liquid.
Solutions for parenteral nutrition. Combinations.
ATC code B05B A10.
The content of nitrogen (L-amino acid series) and calories (glucose and triglycerides) in the Olimel N9E preparation makes it possible to maintain an adequate nitrogen/calorie ratio.
The preparation also contains electrolytes.
The ingredients of the Olimel N9E preparation (amino acids, electrolytes, glucose, and fats) are distributed, metabolized, and excreted by the same pathways as the individual components.
For parenteral nutrition of adults and children over 2 years of age when oral or enteral nutrition is impossible, insufficient, or contraindicated.
Age under 2 years.
Hypersensitivity to egg proteins, soy, peanuts, or corn/corn products (see section "Special warnings and precautions for use"), or to any of the active substances or excipients.
Inborn errors of amino acid metabolism.
Expressed hyperlipidemia or severe lipid metabolism disorders characterized by hypertriglyceridemia.
Severe hyperglycemia.
Pathologically elevated plasma concentrations of sodium, potassium, magnesium, calcium, and/or phosphorus.
No interaction studies have been conducted.
Olimel N9E should not be administered simultaneously with blood through the same infusion system due to the possibility of pseudoagglutination.
Too rapid administration of any complete parenteral nutrition solution may lead to severe or fatal consequences.
Infusion should be stopped immediately if any symptoms of an allergic reaction appear (such as sweating, increased body temperature, chills, headache, skin rash, or shortness of breath).
Potential undesirable effects may occur as a result of incorrect use (e.g., overdose, too high infusion rate) (see sections "Special warnings and precautions for use" and "Overdose").
Olimel N9E is contraindicated for use in children under 2 years of age due to the inappropriate composition and volume (see sections "Pharmacodynamics", "Pharmacokinetics", and "Special warnings and precautions for use").
No studies have been conducted in pediatric patients.
In case of incorrect use (overdose and/or exceeding the recommended infusion rate), signs of hypervolemia and acidosis may appear.
Potential undesirable effects may occur as a result of incorrect use (e.g., overdose, too high infusion rate) (see sections "Special warnings and precautions for use" and "Overdose").
2 years.
Store in the original packaging at a temperature not exceeding 25 °C. Do not freeze. Store in a place inaccessible to children.
Do not add other medicinal products or substances to any of the chambers of the bag or to the reconstituted emulsion without first ensuring their compatibility and stability of the resulting solution (in particular, the stability of the fat emulsion).
Prescription only.
Baxter S.A. / Baxter SA.
Boulevard Rene Branquart 80, Lessines, 7860, Belgium / Boulevard Rene Branquart 80, Lessines, 7860, Belgium.
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.